Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients

Transplantation Reviews

Volumn 23, Issue 2, 2009, Pages 120-128

  Millán, Olga ^a,b   Urtasun, Nerea ^a   Brunet, Mercè ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA MANNOSIDASE; CD134 ANTIGEN; CD40 LIGAND; CD69 ANTIGEN; CD71 ANTIGEN; CYCLOSPORIN; DACLIZUMAB; FAS ANTIGEN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AREA UNDER THE CURVE; ARTICLE; CARDIAC GRAFT REJECTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; ORGAN TRANSPLANTATION; PROTEIN EXPRESSION;

EID: 62349128433     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2009.01.006     Document Type: Article

References (37)

1. Barten M.J., van Gelder T., Gummert J.F., et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2 (2002) 719-732
2. Millan O., Brunet M., Campistol J.M., et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem 49 (2003) 1891-1899
3. Boleslawski E., Conti F., Sanquer S., et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation 77 (2004) 1815-1820
4. Barten M.J., Tarnok A., Garbade J., et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif 40 (2007) 50-63
5. Montero C., Duley J.A., Fairbanks L.D., et al. Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in ribavirin-treated patients using a high performance liquid chromatography linked method. Clin Chim Acta 238 (1995) 169-178
6. Sanquer S., Breil M., Baron C., Dhamane D., Astier A., and Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 65 (1999) 640-648
7. Budde K., Glander P., Kramer B.K., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 83 (2007) 417-424
8. Budde K., Bauer S., Hambach P., et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 7 (2007) 888-898
9. Barten M.J., Gummert J.F., van Gelder T., Shorthouse R., and Morris R.E. Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. J Immunol Methods 253 (2001) 95-112
10. Halloran P.F., Helms L.M., Kung L., and Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 68 (1999) 1356-1361
11. Brunet M., Campistol J.M., Millan O., et al. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). Int Immunopharmacol 3 (2003) 987-999
12. Weimert N.A., Derotte M., Alloway R.R., Woodle E.S., and Vinks A.A. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit 29 (2007) 141-149
13. Langman L.J., LeGatt D.F., Halloran P.F., and Yatscoff R.W. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 62 (1996) 666-672
14. Weigel G., Griesmacher A., Zuckermann A.O., Laufer G., and Mueller M.M. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther 69 (2001) 137-144
15. Millan O., Oppenheimer F., Brunet M., et al. Assessment of mycophenolic acid-induced immunosuppression: a new approach. Clin Chem 46 (2000) 1376-1383
16. Brunet M., Cirera I., Martorell J., et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 81 (2006) 541-546
17. Langman L.J., LeGatt D.F., and Yatscoff R.W. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem 41 (1995) 295-299
18. Glander P., Braun K.P., Hambach P., et al. Non-radioactive determination of inosine 5′-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem 34 (2001) 543-549
19. Glander P., Hambach P., Braun K.P., et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 4 (2004) 2045-2051
20. Sommerer C., Giese T., Schmidt J., Meuer S., and Zeier M. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation 85 (2008) 15-21
21. Sommerer C., Hartschuh W., Enk A., Meuer S., Zeier M., and Giese T. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant (2008)
22. Rostaing L., Puyoo O., Tkaczuk J., et al. Differences in type 1 and type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients. Clin Transplant 13 (1999) 400-409
23. Rostaing L., Tkaczuk J., Durand M., et al. Kinetics of intracytoplasmic Th1 and Th2 cytokine production assessed by flow cytometry following in vitro activation of peripheral blood mononuclear cells. Cytometry 35 (1999) 318-328
24. Barten M.J., Rahmel A., Bocsi J., et al. Cytokine analysis to predict immunosuppression. Cytometry A 69 (2006) 155-157
25. Brunet M., Campistol J.M., Diekmann F., Guillen D., and Millan O. T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. Mol Diagn Ther 11 (2007) 247-256
26. Jorgensen P.F., Wang J.E., Almlof M., et al. Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production. Scand J Immunol 53 (2001) 184-191
27. Ahmed M., Venkataraman R., Logar A.J., et al. Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit 23 (2001) 354-362
28. Stalder M., Birsan T., Holm B., Haririfar M., Scandling J., and Morris R.E. Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther Drug Monit 25 (2003) 22-27
29. Chang D.M., Ding Y.A., Kuo S.Y., Chang M.L., and Wei J. Cytokines and cell surface markers in prediction of cardiac allograft rejection. Immunol Invest 25 (1996) 13-21
30. Berry V., Magill A., Yost M., Janosky J., and Sindhi R. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses. Cytometry A 69 (2006) 95-103
31. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82 (2006) 663-668
32. Braudeau C., Racape M., Giral M., et al. Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int 20 (2007) 845-855
33. Segundo D.S., Ruiz J.C., Izquierdo M., et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 82 (2006) 550-557
34. Sawitzki B., Bushell A., Steger U., et al. Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant 7 (2007) 1091-1102
35. Hooper E., Hawkins D.M., Kowalski R.J., et al. Establishing pediatric immune response zones using the Cylex ImmuKnow assay. Clin Transplant 19 (2005) 834-839
36. Lee T.C., Goss J.A., Rooney C.M., et al. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 20 (2006) 689-694
37. Gras J., Wieers G., Vaerman J.L., et al. Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl 13 (2007) 426-433